Valuation: UCB

Market Cap 53.31B 58.53B 49.12B 44.68B 83.83B 5,420B 88.1B 598B 238B 2,960B 220B 215B 9,291B P/E 2026 *
23.5x
P/E 2027 * 20.5x
Enterprise Value 53.4B 58.63B 49.2B 44.76B 83.96B 5,429B 88.24B 599B 238B 2,965B 220B 215B 9,306B EV / Sales 2026 *
5.87x
EV / Sales 2027 * 5.05x
Free-Float
61.59%
Yield 2026 *
0.52%
Yield 2027 * 0.54%
1 day-1.27%
1 week-5.70%
Current month-0.64%
1 month+27.67%
3 months+28.32%
6 months+17.18%
Current year+17.18%
1 week 277.4
Extreme 277.4
299
1 month 230.1
Extreme 230.1
301.2
Current year 197.45
Extreme 197.45
301.2
1 year 197.45
Extreme 197.45
301.2
3 years 67.08
Extreme 67.08
301.2
5 years 65.4
Extreme 65.4
301.2
10 years 54.84
Extreme 54.84
301.2
Manager TitleAgeSince
Chief Executive Officer 67 01/01/2015
Director of Finance/CFO 60 01/07/2020
Chief Tech/Sci/R&D Officer 59 01/05/2024
Director TitleAgeSince
Director/Board Member 55 01/01/2012
Director/Board Member 67 01/01/2015
Director/Board Member 56 24/04/2014
Date Insider Type Main position Quantity % Market Cap. Importance
1/15/26 A Exercice

Executive/Senior Manager

3,000 0.0015%
1/15/26 A Exercice

Executive/Senior Manager

3,000 0.0015%
1/15/26 A Buy

Director

500 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-1.27%-5.70%+21.78%+309.49% 58.53B
-0.30%-6.68%+29.12%+125.42% 1,200B
+1.25%-5.35%+33.19%+80.42% 651B
+0.94%-2.99%+24.73%+106.93% 506B
-0.60%-1.95%+27.26%+67.32% 377B
+0.69%-9.50%+40.80%+30.23% 330B
+0.41%-4.70%+27.23%+51.59% 288B
+0.81%-4.08%-1.74%+32.71% 272B
-0.15%-6.45%+29.63%+64.18% 236B
-0.06%-0.98%+33.15%+118.99% 206B
Average +0.20%-4.85%+26.51%+98.73% 412B
Weighted average by Cap. +0.37%-5.20%+27.94%+90.64%

Financials

2026 *2027 *
Net sales 9.1B 9.99B 8.39B 7.63B 14.31B 925B 15.04B 102B 40.56B 505B 37.49B 36.7B 1,586B 10.1B 11.09B 9.31B 8.47B 15.88B 1,027B 16.69B 113B 45.02B 561B 41.6B 40.73B 1,760B
Net income 2.31B 2.54B 2.13B 1.94B 3.63B 235B 3.82B 25.92B 10.3B 128B 9.52B 9.32B 403B 2.64B 2.9B 2.43B 2.21B 4.15B 268B 4.36B 29.58B 11.76B 146B 10.86B 10.64B 460B
Net Debt 87.29M 95.84M 80.44M 73.17M 137M 8.87B 144M 979M 389M 4.85B 360M 352M 15.21B -2.27B -2.49B -2.09B -1.9B -3.57B -231B -3.76B -25.48B -10.13B -126B -9.36B -9.16B -396B
Projected Income Statement - Annual - UCB
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
20/11/26 €279.60 -1.27% 252,719
19/11/26 €283.20 -0.67% 203,780
18/11/26 €285.10 -0.59% 235,516
17/11/26 €286.80 -2.81% 303,415
16/11/26 €295.10 -0.47% 195,366
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - UCB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
279.60EUR
Average target price
298.63EUR
Spread / Average Target
+6.81%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - UCB